Earnings Report: Here’s what to expect from ImmuCell (NASDAQ:ICCC)

Earnings results for ImmuCell (NASDAQ:ICCC)

ImmuCell Corporation is expected* to report earnings on 11/12/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. The reported EPS for the same quarter last year was $-0.07.

ImmuCell last announced its quarterly earnings results on August 12th, 2020. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $2.97 million for the quarter. ImmuCell has generated ($0.19) earnings per share over the last year. ImmuCell has confirmed that its next quarterly earnings report will be published on Thursday, November 12th, 2020.

Analyst Opinion on ImmuCell (NASDAQ:ICCC)

1 Wall Street analysts have issued ratings and price targets for ImmuCell in the last 12 months. Their average twelve-month price target is $14.00, predicting that the stock has a possible upside of 148.67%. The high price target for ICCC is $14.00 and the low price target for ICCC is $14.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”

ImmuCell has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $14.00, ImmuCell has a forecasted upside of 148.7% from its current price of $5.63. ImmuCell has received no research coverage in the past 90 days.

Dividend Strength: ImmuCell (NASDAQ:ICCC)

ImmuCell does not currently pay a dividend. ImmuCell does not have a long track record of dividend growth.

Insiders buying/selling: ImmuCell (NASDAQ:ICCC)

In the past three months, ImmuCell insiders have not sold or bought any company stock. Only 13.90% of the stock of ImmuCell is held by insiders. Only 9.31% of the stock of ImmuCell is held by institutions.

Earnings and Valuation of ImmuCell (NASDAQ:ICCC

Earnings for ImmuCell are expected to grow in the coming year, from ($0.24) to ($0.11) per share. The P/E ratio of ImmuCell is -21.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of ImmuCell is -21.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. ImmuCell has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here